Adaptive Biotechnologies Corporation
NASDAQ:ADPTBiotechnology
+$0.61 today
- Market cap
- $4.61B
- Beta
- 2.15
- P/E (TTM)
- -54.5
- EPS (TTM)
- -$0.32
Volume 2.21M
Average 1.94M
ADPT Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Adaptive Biotechnologies CorporationNASDAQ: ADPT
Accumulated OCI · Q2 FY2026 · quarter ended Jun 2026
Accumulated OCI turns negative
Q2 FY2026 Accumulated OCI was -$212K, compared with $73K a year earlier.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -390.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 253K USD
- Year-over-year change
- +52.4%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 253K | +52.4% |
| FY2024 | 2024-12-31 | 166K | -22.8% |
| FY2023 | 2023-12-31 | 215K | +105.2% |
| FY2022 | 2022-12-31 | (4.12M) | -262.0% |
| FY2021 | 2021-12-31 | (1.14M) | — |
Accumulated OCI vs competitors
How ADPT compares with its peers on the latest reported figures
- ADPT's Jun 2026 Accumulated OCI of -$212K is the 6th highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of -390.4% is the 6th highest of 9, against a peer median of -115.4%.
- Accumulated OCI amounts to 0.0% of total assets for ADPT, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $122.6M | +5.8% | +102.7% | 7.3% | |
| Sep 2026 | $1.62M | +1287.2% | — | 0.4% | |
| Jun 2026 | $214K | -99.5% | +5.0% | 0.0% | |
| Mar 2026 | $8K | +147.1% | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | -$212K | -390.4% | — | 0.0% | |
| Mar 2026 | -$494K | -131.2% | — | 0.0% | |
| Sep 2026 | -$914K | -416.3% | — | 0.2% | |
| Jun 2026 | -$2.19M | -21990.0% | — | 0.2% | |
IRONDisc Medicine, Inc. | Sep 2026 | -$2.77M | -485.8% | — | 0.4% |
| Peer median (excluding ADPT) | $0 | -115.4% | +53.8% | 0.2% | |
Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 139.07M | 90.03M | 65.06M | 47.92M | 70.5M |
| Short-term Investments | 214M | 408.17M | 281.34M | 174.37M | 156.49M |
| Net Receivables | 17.41M | 40.06M | 37.97M | 41.73M | 50.37M |
| Inventory | 19.26M | 14.45M | 14.45M | 8.44M | 9.82M |
| Other Current Assets | 0 | 9.44M | 11.37M | 11.29M | 13.02M |
| Total Current Assets | 402.75M | 562.15M | 410.19M | 283.75M | 300.19M |
| Property, Plant & Equipment (Net) | 172.94M | 164.21M | 120.32M | 94.38M | 74.72M |
| Goodwill | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M |
| Intangible Assets | 8.53M | 6.83M | 5.13M | 3.43M | 1.73M |
| Long-term Investments | 217.15M | 0 | 0 | 33.66M | 15.92M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.01M | 4.46M | 6.52M | 5.18M | 1.21M |
| Total Non-current Assets | 520.6M | 294.47M | 250.95M | 255.62M | 212.55M |
| Total Assets | 923.34M | 856.62M | 661.13M | 539.38M | 512.74M |
| Account Payables | 3.31M | 8.08M | 7.72M | 7.27M | 6.47M |
| Short-term Debt | 0 | 0 | 0 | 0 | 13.56M |
| Tax Payables | 391K | 194K | 59K | 176K | 0 |
| Deferred Revenue | 80.46M | 64.12M | 48.63M | 55.69M | 45.19M |
| Other Current Liabilities | 15.64M | 15.94M | 13.69M | 16.7M | 7.7M |
| Total Current Liabilities | 113.81M | 109.79M | 88.02M | 98.05M | 89.92M |
| Long-term Debt | 0 | 0 | 0 | 0 | 196.79M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 98.75M | 58.6M | 44.79M | 27.26M | 1.01M |
| Other Non-current Liabilities | 0 | 125.36M | 130.66M | 132.43M | (70.21M) |
| Total Non-current Liabilities | 205.44M | 282.73M | 264.84M | 238.84M | 197.82M |
| Total Liabilities | 319.24M | 392.52M | 352.86M | 336.89M | 287.74M |
| Common Stock | 14K | 14K | 14K | 14K | 15K |
| Retained Earnings | (718.89M) | (919.08M) | (1.14B) | (1.3B) | (1.36B) |
| Accumulated OCI | (1.14M) | (4.12M) | 215K | 166K | 253K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 110K | (67K) | (121K) | (224K) | 6.21M |
| Total Equity | 604.1M | 464.1M | 308.28M | 202.49M | 225M |
| Total Debt | 111.74M | 108M | 98.77M | 89.39M | 280.58M |
| Net Debt | (27.33M) | 17.97M | 33.71M | 41.47M | 210.09M |
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
Intrinsic Alpha fair value
Locked
Current Price
$28.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.